The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

August 7, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 2017, an international task force  developed updated recommendations for axial and peripheral spondyloarthritis (SpA), as well as psoriatic arthritis (PsA).1

You Might Also Like
  • ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA
Also By This Author
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA

Some drug therapy management recommendations for axial SpA and PsA have used a treat-to-target concept, which has been successfully implemented for other chronic illnesses. The prior recommendations for treating these patients were developed in 2012. At that time, all recommendations for treat-to-target SpA were based on low levels of evidence, consisting mostly of opinions. In the current recommendations, five of the 11 recommendations are based on higher levels of evidence. Five overarching principles and 11 recommendations were developed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Principles of SpA treat-to-target recommendations:

  1. The patient and rheumatologist must share in the decision making for the treatment target;
  2. Treat-to-target by measuring disease activity and adjusting therapy accordingly to improve outcomes;
  3. SpA and PsA are multi-faceted systemic diseases; therefore, managing extra-articular and musculoskeletal manifestations should be coordinated, as needed, between the rheumatologist and other specialists (e.g., dermatologist, gastroenterologist, ophthalmologist);
  4. The goals of SpA and PsA treatment are to optimize long-term health-related quality of life and social participation by controlling disease signs and symptoms, preventing structural damage, normalizing and/or preserving function, avoiding toxicities and minimizing comorbidities; and
  5. Abolishing inflammation is important to achieve treatment goals.

Recommendations:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Clinical remission or inactive disease of musculoskeletal (i.e., arthritis, dactylitis, enthesitis and axial disease) and extra-articular manifestations should be the treatment target;
  2. The treatment target should be individualized based on the current clinical disease manifestations. The treatment modality should be considered when defining the time required to reach the target;
  3. The absence of clinical and laboratory evidence of significant disease activity is the definition of clinical remission and inactive disease;
  4. An alternative treatment target may be low or minimal disease activity;
  5. Disease activity should be measured on the basis of clinical signs and symptoms, and acute phase reactants;
  6. Validated measures of musculoskeletal disease activity and assessment of cutaneous and/or other relevant extra-articular manifestations should be used in clinical practice to define the target and guide treatment decisions. The level of disease activity should dictate the frequency of these measurements;
  7. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure for axial SpA. The Disease Activity index for Psoriatic Arthritis (DAPSA) or Minimal Disease Activity (MDA) should define the target in PsA patients;
  8. The target choice and disease activity measure should consider comorbidities, patient factors and drug-related risks;
  9. Imaging results may be considered in clinical management in addition to clinical and laboratory measures;
  10. After the target is attained, it should be maintained throughout the disease course; and
  11. Treatment target discussions should be achieved with that patient’s involvement and discussion, including informing them about risks and benefits of the strategy planned to reach the target.

Pages: 1 2 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: axial spondyloarthritis (SpA), Guidelines, peripheral spondyloarthritis, recommendations, target

You Might Also Like:
  • ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.